Le Lézard
Classified in: Health
Subjects: CALENDAR OF EVENTS, HEALTH, TRADE SHOWS/SEMINARS/WEBINARS

Xenon to Present at the 43rd Annual J.P. Morgan Healthcare Conference


VANCOUVER, British Columbia and BOSTON, Jan. 07, 2025 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq: XENE), a neuroscience-focused biopharmaceutical company dedicated to discovering, developing, and delivering life-changing therapeutics for patients in need, today announced that the company will present at the 43rd Annual J.P. Morgan Healthcare Conference taking place in San Francisco, CA from January 13-16, 2025.

Company Presentation Details:

Date:

Monday, January 13, 2025

Time:

9:45-10:25 AM Pacific Time (12:45-1:25 PM Eastern Time)

Webcast:

Register here

Presenter:Ian Mortimer, President and Chief Executive Officer, Xenon Pharmaceuticals


A live audio webcast of the company presentation will be available on the "Investors" section of Xenon's website and posted for replay following the event. The above listed dates and times are subject to change.

About Xenon Pharmaceuticals Inc.

Xenon Pharmaceuticals (Nasdaq: XENE) is a neuroscience-focused biopharmaceutical company dedicated to discovering, developing, and delivering life-changing therapeutics. We are advancing an ion channel product portfolio to address areas of high unmet medical need, including epilepsy and depression. Azetukalner, a novel, highly potent, selective Kv7 potassium channel opener, represents the most advanced, clinically validated potassium channel modulator in late-stage clinical development for multiple indications. For more information, please visit www.xenon-pharma.com.

"Xenon" and the Xenon logo are registered trademarks or trademarks of Xenon Pharmaceuticals Inc. in various jurisdictions. All other trademarks belong to their respective owner.

Contacts:
For Investors:
Chad Fugere
Vice President, Investor Relations
(857) 675-7275
[email protected]

For Media:
Colleen Alabiso
Senior Vice President, Corporate Affairs
(617) 671-9238
[email protected]



These press releases may also interest you

at 19:00
Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures, and commercializes high-quality medicines for the treatment of oncology, autoimmune, cardiovascular and metabolic,...

at 14:00
Revolutionising Vascular Access Care for Critically Ill Newborns and Children Key Points: FDA 510(k) Clearance Neonav® ECG Tip Location System is now FDA-cleared, enabling its use in U.S. hospitals to enhance pediatric vascular access...

at 10:19
February 15, 2025 Product:  All Dressed Pizza (U Bake), Super Pizza (U Bake) Issue:  Food - Allergen - Mustard Distribution:  Saskatchewan See the affected products and product photos for this recall SOURCE Canadian Food Inspection Agency (CFIA)

at 07:10
The Bahrain Oncology Centre (BOC) has made medical history by successfully treating a sickle cell disease (SCD) patient using CRISPR-based gene-editing therapy, Casgevy (exagamglogene autotemcel). This marks the first successful treatment of its kind...

at 07:00
Bristol Myers Squibb today announced new five-year results from the POETYK PSO long-term extension (LTE) trial of Sotyktu (deucravacitinib) treatment in adult patients with moderate-to-severe plaque psoriasis. The safety profile of Sotyktu remained...

at 07:00
Independent Pharmacy Cooperative (IPC), the leading Group Purchasing Organization (GPO) for independent pharmacies nationwide, is thrilled to announce a groundbreaking cooperation agreement with Legacy Pharmacy Group (LPG). This strategic partnership...



News published on and distributed by: